Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Company profile
Ticker
ALRN
Exchange
Website
CEO
Dr. James Brian Windsor Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
TURINCO INC
SEC CIK
Corporate docs
Subsidiaries
Lung Therapeutics, LLC • Lung Therapeutics Australia Pty Ltd • Lung Therapeutics Limited ...
ALRN stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
21 Aug 24
8-K
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
8-K
Entry into a Material Definitive Agreement
26 Jul 24
424B5
Prospectus supplement for primary offering
26 Jul 24
424B5
Prospectus supplement for primary offering
26 Jul 24
ARS
2023 FY
Annual report to shareholders
9 Jul 24
DEFA14A
Additional proxy soliciting materials
9 Jul 24
DEF 14A
Definitive proxy
9 Jul 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5 Jun 24
Transcripts
Latest ownership filings
4
Manuel Aivado
22 Aug 24
4
RICKENBACH JOSEF H VON
22 Aug 24
4
William Fairey
22 Aug 24
4
Reinhard J. Ambros
22 Aug 24
4
Alan A Musso
22 Aug 24
4
Change in insider ownership
17 Jun 24
4
Change in insider ownership
12 Jun 24
4
Change in insider ownership
7 Jun 24
3
Timothy M. Cunningham
16 May 24
4/A
Change in insider ownership (amended)
14 May 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.94 mm | 21.94 mm | 21.94 mm | 21.94 mm | 21.94 mm | 21.94 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.01 mm | 2.13 mm | 2.80 mm | 2.14 mm |
Cash used (since last report) | n/a | n/a | 11.44 mm | 8.07 mm | 10.61 mm | 8.13 mm |
Cash remaining | n/a | n/a | 10.51 mm | 13.87 mm | 11.33 mm | 13.82 mm |
Runway (months of cash) | n/a | n/a | 3.5 | 6.5 | 4.1 | 6.5 |
Institutional ownership, Q2 2024
29.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 25 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 13.20 bn |
Total shares | 6.33 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
University Of Texas/texas Am Investment Managment | 1.78 mm | $4.92 bn |
Novartis Bioventures | 1.20 mm | $765.00 k |
Alyeska Investment | 540.00 k | $1.50 bn |
Vanguard | 506.15 k | $1.40 bn |
Nantahala Capital Management | 464.37 k | $1.29 bn |
Cable Car Capital | 420.00 k | $1.16 bn |
Prosight Management | 265.00 k | $734.05 mm |
Biotechnology Value Fund L P | 236.84 k | $0.00 |
Senvest Management | 230.90 k | $575.62 mm |
Geode Capital Management | 170.45 k | $472.14 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Aug 24 | Ambros Reinhard J. | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 2,725 | 6.54 k | 2,725 |
20 Aug 24 | Alan A Musso | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 2,725 | 6.54 k | 2,725 |
20 Aug 24 | William Fairey | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 2,725 | 6.54 k | 2,725 |
20 Aug 24 | Von Rickenbach Josef H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 2,725 | 6.54 k | 2,725 |
20 Aug 24 | Manuel Aivado | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 2,725 | 6.54 k | 2,725 |
News
Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium
14 Oct 24
Aileron Therapeutics Completes Enrollment for Phase 1b IPF Drug Trial, Topline Data Expected Soon
23 Sep 24
Aileron Therapeutics Q2 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate; Cash Position $21.9M
15 Aug 24
Press releases
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
12 Oct 24
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
23 Sep 24
Aileron Therapeutics to Present at the 8th Annual IPF Summit
19 Aug 24
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
14 Aug 24
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
30 Jul 24